- Home
- PCVX vs CHE Comparison
PCVX vs CHE Comparison
Compare PCVX & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | CHE |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.6B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PCVX | CHE |
|---|---|---|
| Price | $54.69 | $373.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $98.33 | ★ $498.00 |
| AVG Volume (30 Days) | ★ 1.1M | 263.8K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 18.34 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | N/A | $6.60 |
| Revenue Next Year | N/A | $6.15 |
| P/E Ratio | ★ N/A | $20.09 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $28.09 | $365.21 |
| 52 Week High | $65.00 | $623.61 |
Technical Indicators
Market Signals| Indicator | PCVX | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 30.31 |
| Support Level | $42.30 | N/A |
| Resistance Level | $56.04 | $458.07 |
| Average True Range (ATR) | 2.27 | 8.95 |
| MACD | -0.35 | -0.85 |
| Stochastic Oscillator | 39.05 | 18.64 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.